Companion diagnostics-a tool to improve pharmacotherapy.

The variability of pharmacotherapy can be of a significant magnitude, and the main reason for this is often diseases heterogeneity. Patients who have similar diagnoses very often respond differently to the same pharmacological intervention, with great variability in both efficacy and safety outcome. Despite having discussed personalized medicine for more than a decade, we still see that most drug prescriptions for severe chronic diseases are largely based on 'trial and error' and not on solid biomarker data. However, with the advance of molecular diagnostics and a subsequent increased understanding of disease mechanisms, things are slowly changing. Within the last few years, we have seen an increasing number of predictive biomarker assays being developed to guide the use of targeted cancer drugs. This type of assay is called companion diagnostics and is developed in parallel to the drug using the drug-diagnostic co-development model. The development of companion diagnostics is a relatively new discipline and in this review, different aspects will be discussed including clinical and regulatory issues. Furthermore, examples of drugs, such as the ALK and PD-1/PD-L1 inhibitors, that have been approved recently together with a companion or complimentary diagnostic will be given.

[1]  Whole Grain Label Statements.  Guidance for Industry and FDA Staff , 2006 .

[2]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[3]  M. Socinski,et al.  NSCLC, metastaticCheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC , 2016 .

[4]  G. Rasi,et al.  Cancer Drug Development and the Evolving Regulatory Framework for Companion Diagnostics in the European Union , 2014, Clinical Cancer Research.

[5]  K. Shadan,et al.  Available online: , 2012 .

[6]  J. T. Jørgensen,et al.  Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives. , 2016, Trends in cancer.

[7]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[8]  J. Lunceford,et al.  Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Munir Pirmohamed,et al.  Pharmacogenomics: Current State-of-the-Art , 2014, Genes.

[10]  M Heath-Chiozzi,et al.  Clinical application of pharmacogenetics. , 2001, Trends in molecular medicine.

[11]  J. T. Jørgensen.  The importance of predictive biomarkers in oncology drug development , 2016, Expert review of molecular diagnostics.

[12]  S. Ramalingam,et al.  Molecular testing prior to first-line therapy in patients with stage IV nonsquamous non-small cell lung cancer (NSCLC): A survey of U.S. medical oncologists. , 2014 .

[13]  J. Spicer,et al.  LBA2_PREGFR MUTATION TESTING AND ONCOLOGIST TREATMENT CHOICE IN ADVANCED NSCLC: GLOBAL TRENDS AND DIFFERENCES , 2015 .

[14]  N. Schork.  Personalized medicine: Time for one-person trials , 2015, Nature.

[15]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[16]  Highly Multiplexed Microbiological / Medical Countermeasure In Vitro Nucleic Acid Based Diagnostic Devices Guidance for Industry and Food and Drug Administration Staff , 2014 .

[17]  J. T. Jørgensen,et al.  Companion Diagnostics for Targeted Cancer Drugs – Clinical and Regulatory Aspects , 2014, Front. Oncol..

[18]  J. T. Jørgensen,et al.  Companion Diagnostics in Oncology - Current Status and Future Aspects , 2013, Oncology.

[19]  C. Milne,et al.  Market watch: Where is personalized medicine in industry heading? , 2015, Nature Reviews Drug Discovery.

[20]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[21]  J. T. Jørgensen.  Are we approaching the post-blockbuster era? Pharmacodiagnostics and rational drug development , 2008, Expert review of molecular diagnostics.

[22]  J. T. Jørgensen.  Clinical application of companion diagnostics. , 2015, Trends in molecular medicine.

[23]  P. Band,et al.  Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer. , 1976, Cancer treatment reports.

[24]  J. T. Jørgensen.  Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC , 2016, Expert review of molecular diagnostics.

[25]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[26]  Bert Vogelstein,et al.  The role of companion diagnostics in the development and use of mutation-targeted cancer therapies , 2006, Nature Biotechnology.

[27]  John Fitzpatrick,et al.  CONCEPT PAPER , 2009 .

[28]  The Development of the HercepTest™ — from Bench to Bedside , 2010, Molecular Diagnostics.

[29]  Guide l’immunothérapie.  VENTANA PD-L1 (SP142) Assay , 2016 .

[30]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.